^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    prednisone

    Company:
    Generic mfg.
    Drug class:
    Steroid receptor agonist
    Related drugs:
    2d
    TREAT-OMG: TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Tang-Du Hospital | Trial completion date: Nov 2024 --> Jun 2026 | Trial primary completion date: Nov 2024 --> Apr 2026
    Trial completion date • Trial primary completion date • Real-world evidence
    |
    prednisone
    2d
    Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW) (clinicaltrials.gov)
    P3, N=36, Recruiting, Ottawa Hospital Research Institute | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> Nov 2025
    Enrollment open • Trial initiation date
    |
    Rituxan (rituximab) • cyclophosphamide • prednisone
    3d
    A Single-Center Prospective Randomized Controlled Clinical Study Evaluating the Efficacy of High-Dose Dexamethasone Followed by Sequential Prednisone Maintenance Therapy in Adults with Newly Diagnosed Immune Thrombocytopenia (ChiCTR2600117105)
    P=N/A, N=170, Not yet recruiting, Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital
    New trial
    |
    Rituxan (rituximab) • prednisone • dexamethasone injection
    3d
    Prospective, single-arm, multicenter clinical study of rituximab combined with cyclophosphamide, mitoxantrone liposomes, vincristine, and prednisone (R-CMOP) regimen in the treatment of previously untreated diffuse large B-cell lymphoma in patients aged 60 years or older or with underlying heart disease (ChiCTR2600117000)
    P=N/A, N=72, Not yet recruiting, The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital of Zhejiang University School of Medicine
    New trial
    |
    Rituxan (rituximab) • cyclophosphamide • prednisone • Marqibo (vincristine liposomal) • Duoenda (mitoxantrone liposomal) • vindesine
    3d
    Analysis of the therapeutic effect of Cognitive Behavioral therapy on Patients with Sudden deafness accompanied by Tinnitus (ChiCTR2600116914)
    P=N/A, N=120, Recruiting, People's Hospital of Deyang city; People's Hospital of Deyang city
    New trial
    |
    prednisone
    3d
    A randomized, double-blinded, placebo-controlled clinical trial of the efficacy and safety of SHR-0302 combine with Prednisone Acetate in the treatment of active arteritis (ChiCTR2500114756)
    P4, N=58, Not yet recruiting, Zhongshan hospital, Fudan University; Zhongshan hospital, Fudan University
    New P4 trial
    |
    prednisone • AiSuDa (ivarmacitinib)
    3d
    Study on the efficacy and safety of abiraterone acetate tablets (II) + ADT + chemotherapy in first-line treatment of mCRPC (ChiCTR2500111854)
    P4, N=36, Not yet recruiting, Affiliated Hospital of Guizhou Medical University; Affiliated Hospital of Guizhou Medical University
    New P4 trial
    |
    docetaxel • abiraterone acetate • prednisone
    3d
    A single-center exploratory study on the efficacy and safety of tetrandrine tablets in the treatment of interstitial lung disease associated with rheumatoid arthritis (ChiCTR2500107574)
    P=N/A, N=60, Recruiting, The First Affiliated Hospital of Army Medical University (Southwest Hospital); The First Affiliated Hospital of Army Medical University (Southwest Hos | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> Nov 2025
    Enrollment open • Trial initiation date
    |
    Rituxan (rituximab) • cyclophosphamide • prednisone • hydroxychloroquine • tofacitinib • CBT-1 (tetrandrine)
    5d
    Cutaneous and Systemic Complications in Primary CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma. (PubMed, Cureus)
    We present the case of a 61-year-old man with CD8+ AECTCL who developed a methicillin-sensitive Staphylococcus aureus port-site infection while on duvelisib following prior gemcitabine/liposomal doxorubicin therapy...Complement studies supported the activation of the alternative pathway, and after multidisciplinary discussion, eculizumab was initiated for TMA management...His cutaneous lymphoma lesions improved with a short course of oral prednisone as directed by oncology. At discharge, he was clinically stable on dialysis with plans for ongoing outpatient care; subsequent follow-up showed stable renal function. This case highlights the intersection between aggressive cutaneous lymphoma, infection, and chemotherapy-induced vascular injury, emphasizing the importance of early recognition of systemic complications in CD8+ AECTCL and the need for a multidisciplinary approach to optimize patient outcomes.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    Copiktra (duvelisib) • prednisone
    6d
    Corticosteroid Effect on Achalasia Variant EGJOO (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Baylor Research Institute | Trial completion date: Jan 2026 --> Nov 2026 | Trial primary completion date: Jan 2026 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    prednisone
    7d
    Risk factors and outcomes for steroid-refractory immune-related hepatotoxicity in locally advanced and metastatic cancer. (PubMed, Cancer Immunol Immunother)
    Patients with Ref-IRH were unlikely to quickly recover with a longer time from initial diagnosis of IRH to resolution to grade 1 (p = 0.002), from peak ALT (p = 0.007), AST (p = 0.011), and TBIL (p = 0.048) to resolution to grade 1, from initial diagnosis of IRH to use of prednisone ≤ 20 mg/day (p = 0.025), and prolonged hospital length of stay (p = 0.017). In conclusion, high IL-6 at diagnosis is a potential risk factor for the development of Ref-IRH. There was no significant difference in efficacy and survival between patients with Ref-IRH and Res-IRH, but much more time from the initial diagnosis of IRH to resolution to grade 1 and the use of immunosuppressive agents is needed for Ref-IRH patients.
    Retrospective data • Journal • IO biomarker
    |
    IL6 (Interleukin 6)
    |
    prednisone
    7d
    Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=31, Completed, Montefiore Medical Center | Active, not recruiting --> Completed
    Trial completion • First-in-human
    |
    abiraterone acetate • prednisone